Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
Feng DC, Li DX, Wu RC, Wang J, Xiao YH, Yoo KH, Ye X, Wei WR, Kong DP, Tuo ZT. Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046. Mil Med Res. 2025;12(1):12.
Alfred Witjes J, Max Bruins H, Carrion A, Cathomas R, Comperat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17–31.
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, et al. European association of urology guidelines on Non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in Situ). Eur Urol. 2022;81(1):75–94.
Ma G, Yang X, Liang Y, Wang L, Li D, Chen Y, Liang Z, Wang Y, Niu H. Precision medicine and bladder cancer heterogeneity. Bull Cancer. 2018;105(10):925–31.
Aziz A, Gierth M, Fritsche HM, May M, Otto W, Denzinger S, Wieland WF, Merseburger A, Riedmiller H, Kocot A, et al. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy. Urol Int. 2013;91(1):97–102.
Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006;12(22):6663–76.
Lin J, Yang J, Xu X, Wang Y, Yu M, Zhu Y. A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts. Cancer Cell Int. 2020;20:402.
Woźnicki P, Laqua FC, Messmer K, Kunz WG, Stief C, Nörenberg D, Schreier A, Wójcik J, Ruebenthaler J, Ingrisch M et al. Radiomics for the Prediction of Overall Survival in Patients with Bladder Cancer Prior to Radical Cystectomy. Cancers (Basel) 2022, 14(18).
Bubendorf L. Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma – FISHing for the right catch. Acta Cytol. 2011;55(2):113–9.
Soria F, Droller MJ, Lotan Y, Gontero P, D’Andrea D, Gust KM, Rouprêt M, Babjuk M, Palou J, Shariat SF. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol. 2018;36(12):1981–95.
Lin T, Liu Z, Liu L, Yang L, Han P, Zhang P, Wei Q. Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma. Oncol Lett. 2017;13(5):3928–34.
Liem E, Oddens JR, Vernooij RWM, Li R, Kamat A, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, et al. The role of fluorescence in situ hybridization for predicting recurrence after adjuvant bacillus Calmette-Guérin in patients with intermediate and high risk nonmuscle invasive bladder cancer: A systematic review and Meta-Analysis of individual patient data. J Urol. 2020;203(2):283–91.
Diao X, Cai J, Zheng J, Kong J, Wu S, Yu H, Huang H, Xie W, Chen X, Huang C et al. Association of chromosome 7 aneuploidy measured by fluorescence in situ hybridization assay with muscular invasion in bladder cancer. Cancer Commun 2020. 40(4):167-180.
Zheng J, Lu S, Huang Y, Chen X, Zhang J, Yao Y, Cai J, Wu J, Kong J, Lin T. Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study. J Transl Med. 2023;21(1):685.
Akaike H. Information theory and an extension of the maximum likelihood principle. In: 2nd international symposium on information theory Abstracts of papers. edn.; 1971: 276–276.
Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.
Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making: Int J Soc Med Decis Mak. 2006;26(6):565–74.
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.
Soukup V, Čapoun O, Cohen D, Hernández V, Burger M, Compérat E, Gontero P, Lam T, Mostafid AH, Palou J, et al. Risk stratification tools and prognostic models in Non-muscle-invasive bladder cancer: A critical assessment from the European association of urology Non-muscle-invasive bladder Cancer guidelines panel. Eur Urol Focus. 2020;6(3):479–89.
Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104.
Waldman FM, Carroll PR, Kerschmann R, Cohen MB, Field FG, Mayall BH. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res. 1991;51(14):3807–13.
Ohta JI, Miyoshi Y, Uemura H, Fujinami K, Mikata K, Hosaka M, Tokita Y, Kubota Y. Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res. 2001;7(8):2463–7.
Ying X, Liu B, Yuan Z, Huang Y, Chen C, Jiang X, Zhang H, Qi D, Yang S, Lin S, et al. METTL1-m(7) G-EGFR/EFEMP1 axis promotes the bladder cancer development. Clin Transl Med. 2021;11(12):e675.
Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, Shariat SF. Prognostic and prediction tools in bladder cancer: A comprehensive review of the literature. Eur Urol. 2015;68(2):238–53.
Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005;23(27):6533–9.
Canter D, Guzzo T, Resnick M, Magerfleisch L, Sonnad S, Bergey M, Tomazewski J, Vaughn D, Van Arsdalen K, Malkowicz B. The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis. BJU Int. 2008;102(8):952–7.
Bolenz C, Herrmann E, Bastian PJ, Michel MS, Wülfing C, Tiemann A, Buchner A, Stief CG, Fritsche HM, Burger M, et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int. 2010;106(4):493–9.
Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016;13(8):471–9.
Werntz RP, Smith ZL, Packiam VT, Smith N, Steinberg GD. The impact of lymphovascular invasion on risk of upstaging and lymph node metastasis at the time of radical cystectomy. Eur Urol Focus. 2020;6(2):292–7.
Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, et al. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011;185(4):1216–21.
Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, et al. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer. 2012;107(11):1826–32.
Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, et al. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU Int. 2013;111(1):74–84.
Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol. 2009;27(24):3929–37.
Zheng J, Kong J, Wu S, Li Y, Cai J, Yu H, Xie W, Qin H, Wu Z, Huang J, et al. Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach. Cancer. 2019;125(24):4388–98.
Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N’Dow J, Nabi G, Cook J, Vale L. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, immunocyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010;14(4):1–331. iii-iv.
Gayed BA, Seideman C, Lotan Y. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol. 2013;190(4):1181–6.
Stordal B, Peters G, Davey R. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance. Genes Chromosomes Cancer. 2006;45(12):1094–105.
Eidelman Y, Salnikov I, Slanina S, Andreev S. Chromosome folding promotes intrachromosomal aberrations under Radiation- and Nuclease-Induced DNA breakage. Int J Mol Sci 2021, 22(22).12186.